Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I dont have level 2 but there a nice spread on the bid/ask right now
Real-Time Best Bid & Ask
0.275 / 0.34
WEST lookings to keep moving today
Bagi also said the float is only about 500k. This thing can fly with some volume...Ill be getting more if it tests lows again
According to Bagi's interview from sept 11 they have inventory and they should be creating revenue as speak now. You guys think its enough to keep from diluting? We should see a new website from all star brands here shortly too I'd assum
I do agree though it looks like they need cash...I read over the last financials and it seems to be hinted at quite a bit.
Going back through NRS...Its just a matter of time before this is trying to set new highs. TapouT should be huge for this co.
The float is low but still need some volume here to really get things going. If anyone could post LVL2 it would be much appreciated. Thx
That was me. sorry cant afford anymore than that right now. Was hoping for a better reaction, maybe as the day progresses. either way cash flow very soon so ill wait it out and see how the sales are.
Top Penny Stocks 10/17/13 October 17, 2013
Top Penny Stocks 10/17/13 October 17, 2013 - @stockstobuy - Twitter
Below is a list of the top 100 penny stocks to watch right now. These penny stocks have the potential to break out to the upside and make a large gain.
See Also - Top Penny Stocks 2014 - Penny Stock Gainers 2013 - Top Stocks for 2014
Top Penny Stocks to Watch - 10/17/13
1. NanoTech Entertainment, Inc. (NTEK)
2. Sigma Labs, Inc. (SGLB)
3. Fannie Mae (FNMA)
4. AMR Corporation (AAMRQ)
5. Freddie Mac (FMCC)
6. Biozone Pharmaceuticals, Inc. (BZNE)
7. The Alkaline Water Company Inc. (WTER)
8. Globalstar Inc. (GSAT)
9. Liquidmetal Technologies Inc. (LQMT)
10. 3D Eye Solutions, Inc. (TDEY)
Cut off the list at 10, cause who really cares about the rest right?
To close above yesterday's high would be a thing of beauty
“Lockheed Martin has been an ideal development partner for this breakthrough application for Liquidmetal Technologies, creating a high precision, high performance part at a lower cost,” said Dr. Bruce Bromage, EVP of Business Development with Liquidmetal Technologies.
As a legit sailor I loved that post! Thanks for that Capt.
A buy signal clicked on for me yesterday and was able to get in below 16c this a.m. Hoping that this is indeed a turnaround from the rangebound stock this has been as of late...
Its gotta break and hold above the 50DMA
Id be estatic with .02
been watching for a few days..couldnt resist .0019 when i saw the the interest peak today...good luck all.
Anyone hearing any rumours as to why the increased volume?
more like 2 rights made 2 wrongs
Could someone post level 2 please, thx
LOI WITH BLOOM BURTON
Sirona Biochem Announces LOI for Collaboration With Bloom Burton & Co.
1 hour ago - ACQUIREMEDIA
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Oct. 8, 2013) - Sirona Biochem Corp. (TSX VENTURE:SBM) (OTCQX:SRBCF) (FRANKFURT:ZSB) and Bloom Burton & Co. ("Bloom Burton") announce the signing of a Letter of Intent to conduct collaborative research to develop and commercialize new therapeutics in the areas of inflammation and infectious disease.
Leveraging Sirona's proprietary fluorination technology platform, Sirona and Bloom Burton will identify and design promising assets, undertake chemical synthesis and scale up, and conduct preclinical proof of concept studies necessary to support further development activities. The collaboration hopes to address rare or neglected inflammatory diseases and the threat of emerging bacterial resistance, both of which are markets with enormous medical need. Sirona and Bloom Burton will share in the future proceeds arising from the commercialization activities.
"Bloom Burton is Canada's leading healthcare-specialized investment banking group," said Neil Belenkie, CEO of Sirona Biochem. "We are proud to be developing a collaborative partnership, where our joint expertise will be combined to develop and transact cutting-edge industry solutions in areas with unmet needs."
"One of Bloom Burton's many advantages is that we see the widest range of opportunities spanning early to late stage assets, at private and public companies across all areas of healthcare," said Bloom Burton President, Brian Bloom. "Through this experience, we understand where needs exist in the marketplace and what investors are seeking. We believe Sirona has an excess of therapeutic opportunities than can be exploited by Sirona alone. We are excited to develop these assets in partnership with Sirona and monetize them at the appropriate time."
About Bloom Burton & Co.
Bloom Burton & Co. exists to accelerate monetization in healthcare. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deeper level of diligence, which combined with a creative and entrepreneurial culture, leads to the right monetizing events for companies and investors. Bloom Burton's many services include capital raising, mergers and acquisitions advisory, equity research, scientific and medical consulting, direct investing, company creation and incubation. For more information, please visit www.bloomburton.com.
About Sirona Biochem
Sirona Biochem is not a traditional biotech company. Sirona is a product-pipeline company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are being developed for both pharmaceutical and cosmetic marketplaces and are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
The boards have been talking for weeks how we wouldnt be incorporated into the iPhone5 yet everyone acts like they are surprised and disappointed. End of yesterday and today are great opportunities to get some cheaper shares before we run back up to 19-20c
Ive always had urges to play the OTC side ofthis stock. Just never understood if both should be the saem SP, you know what I mean? Now that Sbm.V is at 14.5 again is it jsut a matter of time until SRCBF is as well? U'd think so...
As youve prob guessed Im playing the venture side of this but I hope you dont mind the conversation either way...
I thought the saem until thursday and friday. I think some more news is coming...I dont think it would of rebounded the way it has if something isnt up. In fact, I bought more at 14.5 on Friday (on the venture). Rumour has it Neil is quite chapped at the fact that Johnson sold those 2m shares @ 15c saying that they'll regret their decision.
Sirona Biochem Signs LOI with China’s #1 Ranked Anti-Diabetic Company, Wanbang Pharma
Vancouver, British Columbia – August 19, 2013 – Sirona Biochem Corp. (TSX-V: SBM, OTCQX: SRBCF) announced today the signing of a Letter of Intent whereby Sirona Biochem will provide an exclusive license to Wanbang Pharma to develop and commercialize Sirona’s SGLT2 Inhibitor in the People’s Republic of China (PRC). In exchange for this license, Sirona Biochem will receive upfront and milestone payments of up to US$9.5M upon successful achievement of development and regulatory milestones and then royalty payments for product sales in the PRC.
Under the terms of the LOI, Wanbang Pharma will assume responsibility for funding and leading all clinical studies required for Chinese Food and Drug Administration approval. Sirona Biochem will be provided all clinical study results to support new regulatory applications outside of PRC.
“We are excited by the opportunity to work with Wanbang Pharma, the leading anti-diabetic company supplying the largest diabetic population in the world,” said Neil Belenkie, Chief Executive Officer of Sirona Biochem. “With more than 90 million people suffering from diabetes in China and the market growing more than 20% per year, we believe that Wanbang Pharma is uniquely positioned to provide maximum potential to commercialize our SGLT2 Inhibitor in the Chinese marketplace”.
About Wanbang Pharma
Wanbang Biopharmaceuticals is a leading pharmaceutical company in China that specializes in research, production and marketing of medicines for diabetes, cardiovascular disease and endocrinology. Among domestic pharmaceutical companies, Wanbang Pharma is the largest manufacturer and marketer of a comprehensive portfolio of drugs for diabetes.
Wanbang Pharma is a subsidiary of Fosun Pharmaceutical Group which is listed on the Shanghai Stock Exchange (SHA:600196). Fosun Pharma, a major shareholder of Sino Pharma (HKG:1099), the largest drug distributor in China, is part of the Fosun Group, the largest non-state owned enterprise group in China which is listed on the Hong Kong stock exchange (HKG:0656).
About Sirona Biochem
Sirona Biochem is a biotechnology company developing diabetes therapeutics, skin depigmenting and anti-aging agents for cosmetic use, biological ingredients and cancer vaccine antigens. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. Sirona Biochem is the parent company of French-based biotechnology company, TFChem. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Antonia Issa
Communications Manager
Sirona Biochem Corp.
Phone: 1.604.282.6065
Email: aissa@sironabiochem.com
Good to see at least one person is interested in Sirona...you invested in SRBCF or on the canadian side SBM.V?
I agree with 14 as a bottom..but Ive been wrong before, ask my wife.
Possible but the rumours I read are iPhone5s in Sept/Oct and the 6 in 2014...
Most knowledgable investors here know that the Liquidmetal phone doesnt have a chance until iPhone6 which wont bereleased until 2014. Hopefully before March....Hmm, it may all work out perfectly...
Thank you. I was obviously too lazy to do my own dd. 31degrees in Vancouver today. Almost too hot to type...
he sold 400k not sure how many he has...can anyone shed light as to why the prearranged sale? Trying hard to find a positive to CEO selling shares when it seems LQMT might be turning a corner...
Johnny maybe you could answer my question regarding the validation of the LM clubs by the PGA? Im sure the PGA isnt aware of the LM clubs but from your knowledge would they still be PGA approved equipment?
The only reason I had to mention it was u were quite adamant yesterday and early this morning that we would be over 20c but with no real facts to back your opinion.
For both of ours sake I hope we will look back at 20c and laugh...
I should have known better and waited though. i bought some more yesterday in the 18s. A lil impatient but Im sure in time it wont be a concern
So much for 20s eh DBEN? Like I posted yesterday, we are range bound 15-19 until a major development...
I dunno man. I think we will be testing 20 for sometime...at least until a material NR is released. That being said, I cant see sub 14c again...
Yeah I hate debt free companies...
Does anyone know if the golf clubs being designed will be PGA approved. If not they will be all but useless. No one wants to use equipment that isnt PGA compliant...
Yes, seems like no one is really budging either way till they see the numbers...
It was 2010.
There has also been some decent lots bought today.